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Abstract We found that allopurinol, at therapeutically relevant 
concentrations (9-58 μΜ), significantly counteracted copper-
catalysed human non-HDL lipoprotein oxidation, as assessed by 
thiobarbituric acid reactant content and kinetics of conjugated 
diene formation. Oxypurinol was ineffectual. Both drugs had no 
activity on metal-independent, peroxyl radical-induced lipopro-
tein oxidation. Specific fluorescence-quenching experiments 
revealed that only allopurinol could interact with copper 
antagonizing metal binding to lipoproteins. Thus, therapeutic 
allopurinol concentrations can inhibit copper-catalysed lipopro-
tein oxidation through metal complexation, suggesting some 
antioxidant-antiatherogenic activity of the drug in vivo. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Allopurinol has been reported to possess antioxidant prop-
erties, which may partly be attributable to inhibition of tissue 
xanthine oxidase, an enzyme capable of generating reactive 
oxygen species especially under ischemic conditions [1,2]. 
However, a direct scavenging capacity of allopurinol against 
highly reactive prooxidants, such as hydroxyl radical and hy-
pochlorous acid, has been shown [3,4]. Some scavenging-type 
antioxidant effects have also been reported for oxypurinol 
[3,4], which represents the main metabolite of allopurinol in 
vivo [5,6]. Moreover, allopurinol has been shown to exert an 
inhibitory activity against copper-mediated ascorbate and 
D N A oxidation [7]. 
In spite of the aforementioned experimental evidences con-
cerning some antioxidant properties of allopurinol and oxy-
purinol, so far little is known about the effects of these drugs 
on human lipoprotein oxidation, which is usually driven by 
catalytic transition metals, especially copper, and represents a 
focal aspect of atherogenesis [2,8]. The present study, there-
fore, was designed to investigate potential antioxidant effects 
of allopurinol and oxypurinol on human lipoprotein oxidation 
in specific model systems. 
2. Materials and methods 
2.1. Lipoprotein isolation and oxidation 
Reagents were from Sigma Aldrich s.r.l., Milano, Italy, except for 
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2,2'-azobis(amidinopropane) dihydrochloride (AAPH), which was 
from Polisciences, Warrington, USA. 
The non-high-density lipoprotein (non-HDL) fraction was ob-
tained from EDTA plasma of male healthy adults (age 32-60 years) 
essentially as reported by Phelps and Harris [9] and Zhang et al. 
[10], using dextran sulfate (mol. wt. 500000) plus MgCl2 to precipitate 
the fraction itself and remove EDTA. Since prolonged ultracentrifu-
gation and dialysis are avoided with this method, which allows the 
separation of the non-HDL fraction and the removal of EDTA within 
only 90 min [9,10], artifactual lipoprotein oxidation and loss of en-
dogenous antioxidants resulting from these procedures [11,12] are 
minimized [9,10]. It is also noteworthy that the non-HDL fraction 
contains both LDL and VLDL, which are apo-B-containing lipo-
proteins with a recognized oxidisability and atherogenic potential 
[8,13-16]. 
Allopurinol and oxypurinol, pre-dissolved in 5 mM NaOH [6] to 
give initial drug concentrations of l-A mM, were generally used at 
therapeutically relevant final concentrations of 14, 28 and 58 μΜ. In 
this regard, plasma allopurinol and oxypurinol concentrations of 
about 30 and 60 μΜ have been reported in humans after oral admin-
istration of 300 mg allopurinol [5,6]. 
In a first set of experiments, non-HDL lipoproteins (0.15 mg non-
HDL protein/ml) were oxidized by 13 μΜ CuCl2 in phosphate buff-
ered saline (PBS), pH 7.4, allowing 5 h incubation at 37°C with and 
without the drugs. Lipoprotein oxidation was evaluated through a 
thiobarbituric acid (TBA)-dependent test, which can detect mono-
and bi-functional aldehydic products of lipid peroxidation implicated 
in the atherogenic modifications of the lipoprotein particle [8]. TBA 
reactive substances (TBARS) were measured basically according to 
Ohkawa et al. [17], with some modifications. A suitable aliquot of 
the non-HDL sample was added to a reaction mixture containing 
0.25 mM EDTA, 20 μΜ butylated hydroxytoluene in absolute etha-
nol, 0.1 ml of 8.1% sodium dodecyl sulfate, 1.3 ml of 20% acetic acid, 
pH 3.5, and 1.3 ml aqueous solution of 0.6% TBA, followed by 30 min 
heating at 95°C. After cooling, the chromogen was extracted with n-
butanol and read spectrophotometrically at 532 against an appropri-
ate blank. Results were calculated as nmol TBARS/mg non-HDL 
protein, using a molar extinction coefficient of 154 000. The drugs 
gave no interference in the TBA-test. 
In other specific experiments, the effects of allopurinol and oxypu-
rinol on the kinetics of copper-catalysed human non-HDL lipoprotein 
oxidation were investigated through continuous spectrophotometric 
monitoring of absorbance increase at 234 nm, reflecting conjugated 
dienes (CD) formation during lipid peroxidation [8,11,18]. Molar ex-
tinction coefficient of CD was considered to be 29 500 at 234 nm [11]. 
Since the VLDL-containing non-HDL lipoprotein fraction may be 
characterized by a slight turbidity which is favored by higher copper 
concentrations, in these UV experiments the content of lipoprotein 
and CuCi2 was lowered to 0.1 mg non-HDL protein/ml and 8 μΜ, 
respectively. Drug concentrations were also decreased to 9, 17 and 
37 μΜ, so that drugxopper molar ratios were similar to those of 
the first set of experiments. Incubation was at 37°C in quartz cuvettes 
containing PBS, pH 7.4; reference cuvettes contained lipoprotein or 
lipoprotein plus various drug concentrations, where appropriate, in 
PBS, pH 7.4. 
Finally, non-HDL lipoproteins (0.15 mg non-HDL protein/ml) were 
oxidized using a metal ion-independent prooxidant, namely the per-
oxyl radical-generating azo-initiator AAPH at 4 mM final concentra-
tion in the presence of 0.1 mM diethylenetriaminepentaacetic acid 
[19]; incubation was for 5 h at 37°C in PBS, pH 7.4, with and without 
14, 28 and 58 μΜ allopurinol or oxypurinol. Lipoprotein oxidation 
was evaluated through the TBA-test, as reported above. 
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Non-HDL-protein was measured by the method of Lowry et al. 
[20]. 
2.2. Drug-copper interaction 
Copper complexation is a key aspect of the pharmacological antag-
onism of lipoprotein oxidation [2,8,21]; such a complexation by a 
drug may prevent metal binding to the particle apo B 100 moiety, 
which is an essential requisite for copper-mediated lipoprotein oxida-
tion [8,21]. To investigate possible copper-binding properties of allo-
purinol and oxypurinol, drug fluorescence-quenching experiments 
were specifically carried out for oxypurinol, which shows an intrinsic 
fluorescence. Indeed, the relative fluorescence of a substance can be 
quenched by catalytic transition metals, as a result of formation of a 
complex between such a substance and metals themselves [22]. Exci-
tation and emission wavelengths of oxypurinol were determined to be 
390 and 450 nm, respectively; the drug was used at final concentra-
tions of 100 and 200 μΜ, while the concentration of CuCl2 (which 
gave no interference at the aforementioned wavelengths) ranged from 
5 to 120 μΜ. 
Another fluorescence-quenching methodological approach was spe-
cifically used for allopurinol, which does not apparently show an 
intrinsic fluorescence. Such an approach, which was however applied 
also to oxypurinol, is based on the quenching of the endogenous 
tryptophan-related lipoprotein fluorescence by copper [8,23,24], a phe-
nomenon which may be counteracted by substances able to bind the 
metal. Optimal operative conditions were found using non-HDL lipo-
proteins at a final protein content of 5.5 μg/ml, 5 μΜ Q1CI2 and drug 
concentrations ranging from 5 to 100 μΜ. Fluorescence emission 
spectra were recorded after excitation at 280 nm, the emission values 
around 335 nm being related to lipoprotein tryptophan residues 
[23,24]. 
2.3. Statistics 
Data were calculated as means ±SD of 7 different experiments, 
unless otherwise indicated. Specific drug effects were evaluated by 
the one-way analysis of variance (ANOVA) plus Student-Newman-
Keuls test [25]. P<0.05 was regarded as statistically significant [25], 
3. Results 
3.1. Drug effects on lipoprotein oxidation 
In the tests where the drugs were ineffective, we will report 
Table 1 
Effect of allopurinol on copper-mediated human non-HDL lipopro-
tein oxidation 
nmol TBARS/mg non-HDL 
protein 
Control 
Control plus: 
14 μΜ allopurinol 
28 μΜ allopurinol 
58 μΜ allopurinol 
54.8 ±15.3 
37.5±9.5 a 
24.7 ±7.5 a-b 
18.5 ± 7.0 a 
Lipoprotein oxidation was induced by 5 h incubation at 37°C with 
13 μΜ CuCl2 in PBS, pH 7.4, and evaluated through the TBA-test 
(see Section 2 for further explanations). 
Means ± SD of 7 different experiments. 
11 P<0 .05 vs control; b P<0 .05 vs the value that precedes (one-way 
analysis of variance plus Student-Newman-Keuls test). 
only the results observed with the highest therapeutic drug 
concentrations. 
As shown in Table 1, allopurinol, beginning from 14 μ Μ , 
was inhibitory on copper-catalysed n o n - H D L lipoprotein ox-
idation and TBARS formation. The drug at 58 μ Μ was not 
significantly more effective than at 28 μ Μ ; thus, a virtually 
maximal antioxidant capacity of allopurinol may be consid-
ered to be operative at a drug:copper molar ratio of 2 : 1 . On 
the other hand, oxypurinol had no specific antioxidant activ-
ity; in fact, 53.7 ±14 .5 nmol TBARS/mg n o n - H D L protein 
were detected in the presence of 58 μ Μ oxypurinol, not differ-
ent from the values observed in control experiments 
(54.8 ±15 .3 nmol TBARS/mg n o n - H D L protein, P = NS). 
Allopurinol also showed antioxidant effects on the kinetics 
of copper-mediated n o n - H D L lipoprotein oxidation (Fig. 1). 
Lag time of oxidation was 52 ± 6 min in control experiments, 
and it was markedly prolonged by the drug (92.5 ±13 .5 , 
154.5 ± 24 and 186 ± 38 min with 9, 17 and 37 μ Μ allopurinol, 
respectively, all P < 0 . 0 5 vs control ; 17 and 37 μ Μ vs 9 μ Μ , 
P < 0.05; n = 5). Moreover, oxidation rate was significantly 
100.0 
Time (min) 
Fig. 1. Antioxidant activity of allopurinol on copper-catalysed human non-HDL lipoprotein oxidation. Lipoproteins were incubated at 37°C in 
PBS, pH 7.4, with 8 μΜ CuCl2 in the absence (trace 1, control) or presence of 9, 17 and 37 μΜ allopurinol (traces 2, 3 and 4, respectively). 
Conjugated diene formation during oxidation was followed spectrophotometrically as an increase of absorbance at 234 nm (A2 ). The figure 
represents results from a typical kinetic experiment (see Sections 2 and 3 for further explanations). 
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decreased by allopurinol (from 2.45 ±0.55 nmol CD/min/mg 
non-HDL protein of control experiments to 1.33 ±0.45, 
0.83 ±0.4 and 0.55 ±0.3 nmol CD/min/mg non-HDL protein 
with 9, 17 and 37 μΜ allopurinol, respectively, all P<0 .05 vs 
control; 37 vs 9 μΜ, ¿><0.05; ra = 5). Thus, the kinetics of 
pharmacological inhibition of lipoprotein oxidation character-
ized also by a decreased propagation rate suggests that allo-
purinol may have copper binding and not radical scavenging 
OH 
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Fig. 3. Chemical structure of allopurinol and oxypurinol. 
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Fig. 2. Inhibition of copper-induced lipoprotein fluorescence quench-
ing by allopurinol. Traces: A, non-HDL lipoprotein alone (5.5 μg 
non-HDL protein/ml); B, non-HDL lipoprotein (5.5 μg non-HDL 
protein/ml) plus 5 μΜ CuCl2 and 10 μΜ allopurinol; C, non-HDL 
lipoprotein (5.5 μg non-HDL protein/ml) plus 5 μΜ Q1CI2 and 
5 μΜ allopurinol; D, non-HDL lipoprotein (5.5 μg non-HDL pro-
tein/ml) plus 5 μΜ CuCb and 50 μΜ oxypurinol; E, non-HDL 
lipoprotein (5.5 μg non-HDL protein/ml) plus 5 μΜ CuCl2. The fig-
ure represents a fluorescence emission spectrum of non-HDL lipo-
protein after excitation at 280 nm (see Sections 2 and 3 for further 
explanations). 
properties [18]. Oxypurinol, however, showed no specific anti-
oxidant activity (lag time and oxidation rate of 53 ± 6.7 min 
and 2.6 ± 0.7 nmol CD/min/mg non-HDL protein with 37 μΜ 
oxypurinol, as compared to 52 ± 7.3 min and 2.45 ± 0.55 nmol 
CD/min/mg non-HDL protein of controls, P = NS; n = 5). 
When non-HDL lipoproteins were oxidized in a metal-in-
dependent fashion through peroxyl radicals generated ther-
mally by the azo-initiator AAPH, both allopurinol and oxy-
purinol were ineffective. In fact, 21.6 ± 7.3 and 21.8 ± 6.9 nmol 
TBARS/mg non-HDL protein were detected with 58 μΜ al-
lopurinol and oxypurinol, respectively, as compared to 
22.05 ± 7.5 nmol TBARS/mg non-HDL protein of controls 
(P = NS; M = 5). These results further suggest that the antiox-
idant effects of allopurinol against copper-mediated lipopro-
tein oxidation are not due to scavenging of peroxyl (or alkox-
yl) radicals, which represent the main lipoperoxidation 
propagating species [2,8]. 
3.2. Drug-copper interaction 
Fluorescence of oxypurinol was not quenched by copper, 
indicating no metal binding capacity of the drug. Indeed, 
under the experimental conditions used, fluorescence values 
of 100 and 200 μΜ oxypurinol alone were 2.9 ±0.3 and 
5.7 ± 0.6 units of relative fluorescence, not significantly differ-
ent from those detected, for example, with 100 and 200 μΜ 
oxypurinol plus 100 μΜ CuCl2 (2.75 ±0.2 and 5.8 ±0.55 units 
of relative fluorescence, respectively, _P = NS; n = 5). 
As depicted in Fig. 2, the intrinsic lipoprotein fluorescence 
(trace A) underwent a marked quenching by 5 μΜ Q1CI2 with 
decreased emission values around 335 nm (trace E), suggesting 
metal binding to and degradation of the tryptophan residues 
of the particle protein moiety [8,23,24]. In line with the lipo-
protein oxidation experiments, 5 and 10 μΜ allopurinol (Fig. 
2, traces C and B, respectively), but not 50 μΜ oxypurinol 
(Fig. 2, trace D), counteracted copper-mediated lipoprotein 
fluorescence quenching in a dose-related fashion, pointing to 
specific metal binding by allopurinol with protection of crit-
ical tryptophan residues against copper oxidative attack. In-
hibition of copper-induced lipoprotein fluorescence quenching 
by allopurinol was apparently maximal at a drug:copper mo-
lar ratio of 2:1; indeed, increasing allopurinol concentrations 
up to 100 μΜ was not further inhibitory, and oxypurinol, 
even at 100 μΜ, was ineffective (not shown). 
4. Discussion 
The present study shows that allopurinol significantly coun-
teracts copper-driven human lipoprotein oxidation, pointing 
to copper complexation as the mechanism involved in specific 
drug antioxidant activity. Interestingly oxypurinol, although 
structurally similar to allopurinol (Fig. 3), has apparently no 
antioxidant effect. It is evident that the insertion of a further 
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hydroxyl group in the pyrimidine-type heteroaromatic ring of 
allopurinol to form oxypurinol (Fig. 3) results in a loss of the 
endogenous antioxidant capacity. In such a context, it is pos-
sible that copper complexation by allopurinol is related to the 
unused metal electrons which interact with molecular orbitals 
in the drug ligand. These electrons made available by the 
metal may then flow in the direction of the aromatic ring, 
reinforcing ligand-metal bond [26]. The further hydroxyl 
group of oxypurinol could dissociate to form 0~, the unused 
electron of which might migrate in direction of the hetero-
aromatic ring, resulting in higher molecular stability with in-
capability of the ring itself to accept electrons from catalytic 
transition metals. 
Allopurinol may reach concentrations of about 30 μΜ in 
human plasma after oral drug administration of 300 mg [5,6]. 
It is worth emphasizing, therefore, that the antioxidant effects 
of allopurinol herewith reported are evident at therapeutically 
relevant concentrations. On the other hand, allopurinol has a 
short half-life in human plasma, since it is rapidly metabolized 
to oxypurinol [5,6]. Hence, a specific antioxidant activity of 
allopurinol in vivo might be somehow questioned. However, it 
has been reported than the patients subjected to long-term 
therapy with allopurinol show a slower drug metabolism 
than those receiving single doses of the drug [27]; moreover, 
allopurinol is present not only in the plasma environment, but 
also at tissue level [27]. This latter aspect appears relevant, 
considering that lipoprotein oxidation may not occur in the 
bloodstream due to the high antioxidant capacity of plasma, 
but, rather, directly in the vascular tissue [28]. It is noteworthy 
that copper is particularly active at promoting lipoprotein 
oxidation as a result of its peculiar ability to bind to the 
particle apo B 100 moiety even in the presence of phosphates 
[29], and that redox-active copper has been detected in human 
atherosclerotic lesions [30], pointing to copper as a mediator 
of prooxidant-atherogenic responses in vivo [2,8,29,30]. Thus, 
allopurinol, once present especially in the vascular tissue dur-
ing chronic therapy, could directly counteract copper-medi-
ated lipoprotein oxidation and atherogenic processes. Such 
an issue deserves further clinical and epidemiological studies. 
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